Concept
Lyrfigtu Approval
10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE / 9. Lyrfigtu for FGFR2-Positive Bile Duct Cancer
"Lyrfigtu (lirafugratinib), a once-daily pill, is for previously treated cholangiocarcinoma with an FGFR2 fusion or rearrangement. Tumors shrank in 46% of patients, and responses lasted a median of 11.8 months."
Related Ideas
- September Options10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
- Treatment Findings10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
- Testing10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 2. Hyrnuo as a First Treatment for HER2-Mutant Lung Cancer
- Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 2. Hyrnuo as a First Treatment for HER2-Mutant Lung Cancer
- Etcamah Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 1. Etcamah for ESR1-Mutated Breast Cancer
- Treatment Options10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
- Treatment Combination10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
- Bexlutry Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · References: